Cargando…

Characterization of Entamoeba histolytica adenosine 5′-phosphosulfate (APS) kinase; validation as a target and provision of leads for the development of new drugs against amoebiasis

BACKGROUND: Amoebiasis, caused by Entamoeba histolytica infection, is a global public health problem. However, available drugs to treat amoebiasis are currently limited, and no effective vaccine exists. Therefore, development of new preventive measures against amoebiasis is urgently needed. METHODOL...

Descripción completa

Detalles Bibliográficos
Autores principales: Mi-ichi, Fumika, Ishikawa, Takeshi, Tam, Vo Kha, Deloer, Sharmina, Hamano, Shinjiro, Hamada, Tsuyoshi, Yoshida, Hiroki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715247/
https://www.ncbi.nlm.nih.gov/pubmed/31425516
http://dx.doi.org/10.1371/journal.pntd.0007633
_version_ 1783447206486867968
author Mi-ichi, Fumika
Ishikawa, Takeshi
Tam, Vo Kha
Deloer, Sharmina
Hamano, Shinjiro
Hamada, Tsuyoshi
Yoshida, Hiroki
author_facet Mi-ichi, Fumika
Ishikawa, Takeshi
Tam, Vo Kha
Deloer, Sharmina
Hamano, Shinjiro
Hamada, Tsuyoshi
Yoshida, Hiroki
author_sort Mi-ichi, Fumika
collection PubMed
description BACKGROUND: Amoebiasis, caused by Entamoeba histolytica infection, is a global public health problem. However, available drugs to treat amoebiasis are currently limited, and no effective vaccine exists. Therefore, development of new preventive measures against amoebiasis is urgently needed. METHODOLOGY/PRINCIPAL FINDINGS: Here, to develop new drugs against amoebiasis, we focused on E. histolytica adenosine 5′-phosphosulfate kinase (EhAPSK), an essential enzyme in Entamoeba sulfolipid metabolism. Fatty alcohol disulfates and cholesteryl sulfate, sulfolipids synthesized in Entamoeba, play important roles in trophozoite proliferation and cyst formation. These processes are closely associated with clinical manifestation and severe pathogenesis of amoebiasis and with disease transmission, respectively. We validated a combination approach of in silico molecular docking analysis and an in vitro enzyme activity assay for large scale screening. Docking simulation ranked the binding free energy between a homology modeling structure of EhAPSK and 400 compounds. The 400 compounds were also screened by a 96-well plate-based in vitro APSK activity assay. Among fifteen compounds identified as EhAPSK inhibitors by the in vitro system, six were ranked by the in silico analysis as having high affinity toward EhAPSK. Furthermore, 2-(3-fluorophenoxy)-N-[4-(2-pyridyl)thiazol-2-yl]-acetamide, 3-phenyl-N-[4-(2-pyridyl)thiazol-2-yl]-imidazole-4-carboxamide, and auranofin, which were identified as EhAPSK inhibitors by both in silico and in vitro analyses, halted not only Entamoeba trophozoite proliferation but also cyst formation. These three compounds also dose-dependently impaired the synthesis of sulfolipids in E. histolytica. CONCLUSIONS/SIGNIFICANCE: Hence, the combined approach of in silico and in vitro-based EhAPSK analyses identified compounds that can be evaluated for their effects on Entamoeba. This can provide leads for the development of new anti-amoebic and amoebiasis transmission-blocking drugs. This strategy can also be applied to identify specific APSK inhibitors, which will benefit research into sulfur metabolism and the ubiquitous pathway terminally synthesizing essential sulfur-containing biomolecules.
format Online
Article
Text
id pubmed-6715247
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-67152472019-09-10 Characterization of Entamoeba histolytica adenosine 5′-phosphosulfate (APS) kinase; validation as a target and provision of leads for the development of new drugs against amoebiasis Mi-ichi, Fumika Ishikawa, Takeshi Tam, Vo Kha Deloer, Sharmina Hamano, Shinjiro Hamada, Tsuyoshi Yoshida, Hiroki PLoS Negl Trop Dis Research Article BACKGROUND: Amoebiasis, caused by Entamoeba histolytica infection, is a global public health problem. However, available drugs to treat amoebiasis are currently limited, and no effective vaccine exists. Therefore, development of new preventive measures against amoebiasis is urgently needed. METHODOLOGY/PRINCIPAL FINDINGS: Here, to develop new drugs against amoebiasis, we focused on E. histolytica adenosine 5′-phosphosulfate kinase (EhAPSK), an essential enzyme in Entamoeba sulfolipid metabolism. Fatty alcohol disulfates and cholesteryl sulfate, sulfolipids synthesized in Entamoeba, play important roles in trophozoite proliferation and cyst formation. These processes are closely associated with clinical manifestation and severe pathogenesis of amoebiasis and with disease transmission, respectively. We validated a combination approach of in silico molecular docking analysis and an in vitro enzyme activity assay for large scale screening. Docking simulation ranked the binding free energy between a homology modeling structure of EhAPSK and 400 compounds. The 400 compounds were also screened by a 96-well plate-based in vitro APSK activity assay. Among fifteen compounds identified as EhAPSK inhibitors by the in vitro system, six were ranked by the in silico analysis as having high affinity toward EhAPSK. Furthermore, 2-(3-fluorophenoxy)-N-[4-(2-pyridyl)thiazol-2-yl]-acetamide, 3-phenyl-N-[4-(2-pyridyl)thiazol-2-yl]-imidazole-4-carboxamide, and auranofin, which were identified as EhAPSK inhibitors by both in silico and in vitro analyses, halted not only Entamoeba trophozoite proliferation but also cyst formation. These three compounds also dose-dependently impaired the synthesis of sulfolipids in E. histolytica. CONCLUSIONS/SIGNIFICANCE: Hence, the combined approach of in silico and in vitro-based EhAPSK analyses identified compounds that can be evaluated for their effects on Entamoeba. This can provide leads for the development of new anti-amoebic and amoebiasis transmission-blocking drugs. This strategy can also be applied to identify specific APSK inhibitors, which will benefit research into sulfur metabolism and the ubiquitous pathway terminally synthesizing essential sulfur-containing biomolecules. Public Library of Science 2019-08-19 /pmc/articles/PMC6715247/ /pubmed/31425516 http://dx.doi.org/10.1371/journal.pntd.0007633 Text en © 2019 Mi-ichi et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Mi-ichi, Fumika
Ishikawa, Takeshi
Tam, Vo Kha
Deloer, Sharmina
Hamano, Shinjiro
Hamada, Tsuyoshi
Yoshida, Hiroki
Characterization of Entamoeba histolytica adenosine 5′-phosphosulfate (APS) kinase; validation as a target and provision of leads for the development of new drugs against amoebiasis
title Characterization of Entamoeba histolytica adenosine 5′-phosphosulfate (APS) kinase; validation as a target and provision of leads for the development of new drugs against amoebiasis
title_full Characterization of Entamoeba histolytica adenosine 5′-phosphosulfate (APS) kinase; validation as a target and provision of leads for the development of new drugs against amoebiasis
title_fullStr Characterization of Entamoeba histolytica adenosine 5′-phosphosulfate (APS) kinase; validation as a target and provision of leads for the development of new drugs against amoebiasis
title_full_unstemmed Characterization of Entamoeba histolytica adenosine 5′-phosphosulfate (APS) kinase; validation as a target and provision of leads for the development of new drugs against amoebiasis
title_short Characterization of Entamoeba histolytica adenosine 5′-phosphosulfate (APS) kinase; validation as a target and provision of leads for the development of new drugs against amoebiasis
title_sort characterization of entamoeba histolytica adenosine 5′-phosphosulfate (aps) kinase; validation as a target and provision of leads for the development of new drugs against amoebiasis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715247/
https://www.ncbi.nlm.nih.gov/pubmed/31425516
http://dx.doi.org/10.1371/journal.pntd.0007633
work_keys_str_mv AT miichifumika characterizationofentamoebahistolyticaadenosine5phosphosulfateapskinasevalidationasatargetandprovisionofleadsforthedevelopmentofnewdrugsagainstamoebiasis
AT ishikawatakeshi characterizationofentamoebahistolyticaadenosine5phosphosulfateapskinasevalidationasatargetandprovisionofleadsforthedevelopmentofnewdrugsagainstamoebiasis
AT tamvokha characterizationofentamoebahistolyticaadenosine5phosphosulfateapskinasevalidationasatargetandprovisionofleadsforthedevelopmentofnewdrugsagainstamoebiasis
AT deloersharmina characterizationofentamoebahistolyticaadenosine5phosphosulfateapskinasevalidationasatargetandprovisionofleadsforthedevelopmentofnewdrugsagainstamoebiasis
AT hamanoshinjiro characterizationofentamoebahistolyticaadenosine5phosphosulfateapskinasevalidationasatargetandprovisionofleadsforthedevelopmentofnewdrugsagainstamoebiasis
AT hamadatsuyoshi characterizationofentamoebahistolyticaadenosine5phosphosulfateapskinasevalidationasatargetandprovisionofleadsforthedevelopmentofnewdrugsagainstamoebiasis
AT yoshidahiroki characterizationofentamoebahistolyticaadenosine5phosphosulfateapskinasevalidationasatargetandprovisionofleadsforthedevelopmentofnewdrugsagainstamoebiasis